Increased glucose metabolism of inflammatory tissues is the main source of false-positive
18F-FDG PET findings in oncology. It has been suggested that radiolabeled nucleosides …

INTRODUCTION: The goal of this study was to compare the glucose analog, 2-[18F] fluoro-2-
deoxy-d-glucose ([18F]-FDG), the amino acid analog, o-(2-[18F] fluoroethyl)-l-tyrosine ([18F] …

Many clinical PET studies have shown that increased 18F-FDG uptake is not specific to
malignant tumors. 18F-FDG is also taken up in inflammatory lesions, particularly in …

The aim of this study was to investigate the difference in the rates of FDG uptake between
malignant and inflammatory cells and processes. Methods: In vitro studies: 18F-FDG uptake …

3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) has been suggested as a new PET tracer for
imaging tumor proliferation. We investigated the use of 18F-FLT to monitor the response of …

Novel radiopharmaceuticals for the detection of tumors and their metastases may be of
clinical interest if they are more tumor selective than 18F-FDG. Increased glucose …

Deoxy-3′-[18F] fluorothymidine ([18F] FLT) has been proposed as a new marker for
imaging tumor proliferation by positron emission tomography (PET). The uptake of [18F] FLT …

Recently, the thymidine analog 3′-deoxy-3′-18F-fluorothymidine (FLT) was suggested for
imaging tumoral proliferation. In this prospective study, we examined whether 18F-FLT …

18F-FDG PET has gained acceptance for staging of esophageal cancer. However, FDG is
not tumor specific and false-positive results may occur by accumulation of FDG in benign …

Medicine (1). Although the use of PET has exploded within the last few years, this has
primarily resulted from the application of 18F-FDG in oncology research and clinical …